Morgan Stanley
ORMP icon

Morgan Stanley’s Oramed Pharmaceuticals ORMP Stock Holding History

Morgan Stanley’s Portfolio ORMP Stock Details ORMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$47.8K Sell
14,052
-3,582
-20% -$12.2K ﹤0.01% 6440
2025
Q4 		$50.3K Buy
17,634
+710
+4% +$1.83K ﹤0.01% 6438
2025
Q3 		$44.7K Sell
16,924
-15,171
-47% -$33.5K ﹤0.01% 6449
2025
Q2 		$72.2K Sell
32,095
-3,730
-10% -$8.23K ﹤0.01% 6237
2025
Q1 		$76.7K Buy
35,825
+1,192
+3% +$2.75K ﹤0.01% 6129
2024
Q4 		$83.8K Sell
34,633
-10,020
-22% -$23.8K ﹤0.01% 6124
2024
Q3 		$109K Sell
44,653
-781
-2% -$1.9K ﹤0.01% 5974
2024
Q2 		$117K Buy
45,434
+725
+2% +$1.72K ﹤0.01% 5910
2024
Q1 		$131K Sell
44,709
-83,775
-65% -$234K ﹤0.01% 5885
2023
Q4 		$297K Buy
128,484
+67,970
+112% +$145K ﹤0.01% 5796
2023
Q3 		$158K Buy
60,514
+16,724
+38% +$52.7K ﹤0.01% 5691
2023
Q2 		$157K Sell
43,790
-240,346
-85% -$771K ﹤0.01% 5747
2023
Q1 		$619K Sell
284,136
-32,255
-10% -$102K ﹤0.01% 5130
2022
Q4 		$3.81M Sell
316,391
-210,715
-40% -$1.64M ﹤0.01% 3985
2022
Q3 		$3.42M Sell
527,106
-159,745
-23% -$1.29M ﹤0.01% 3997
2022
Q2 		$3.15M Buy
686,851
+92,823
+16% +$496K ﹤0.01% 4167
2022
Q1 		$5.14M Buy
594,028
+207,408
+54% +$2.12M ﹤0.01% 3661
2021
Q4 		$5.52M Buy
386,620
+266,615
+222% +$5.57M ﹤0.01% 3618
2021
Q3 		$2.64M Buy
120,005
+37,339
+45% +$636K ﹤0.01% 4346
2021
Q2 		$1.11M Buy
82,666
+69,210
+514% +$792K ﹤0.01% 5022
2021
Q1 		$137K Buy
13,456
+5,240
+64% +$43K ﹤0.01% 5858
2020
Q4 		$35K Buy
8,216
+2,475
+43% +$8.05K ﹤0.01% 6266
2020
Q3 		$15K Sell
5,741
-854
-13% -$2.98K ﹤0.01% 6150
2020
Q2 		$23K Buy
6,595
+159
+2% +$534 ﹤0.01% 5975
2020
Q1 		$19K Sell
6,436
-16,739
-72% -$73.3K ﹤0.01% 5832
2019
Q4 		$120K Sell
23,175
-7,622
-25% -$28.6K ﹤0.01% 5591
2019
Q3 		$98K Buy
30,797
+2,545
+9% +$8.48K ﹤0.01% 5450
2019
Q2 		$101K Buy
28,252
+1,551
+6% +$5.47K ﹤0.01% 5317
2019
Q1 		$97K Sell
26,701
-1,693
-6% -$5.6K ﹤0.01% 5409
2018
Q4 		$85K Sell
28,394
-1,040
-4% -$4.31K ﹤0.01% 5607
2018
Q3 		$143K Sell
29,434
-5
-0% -$26 ﹤0.01% 5581
2018
Q2 		$219K Sell
29,439
-4,448
-13% -$32.3K ﹤0.01% 5498
2018
Q1 		$220K Sell
33,887
-2,107
-6% -$16.3K ﹤0.01% 5429
2017
Q4 		$324K Buy
35,994
+21,228
+144% +$203K ﹤0.01% 5213
2017
Q3 		$147K Buy
14,766
+2,131
+17% +$18.4K ﹤0.01% 5466
2017
Q2 		$98K Sell
12,635
-397
-3% -$2.99K ﹤0.01% 5642
2017
Q1 		$80K Sell
13,032
-2,828
-18% -$17.6K ﹤0.01% 5681
2016
Q4 		$97K Sell
15,860
-179
-1% -$1.17K ﹤0.01% 5581
2016
Q3 		$117K Sell
16,039
-22,453
-58% -$175K ﹤0.01% 5248
2016
Q2 		$321K Buy
38,492
+34,683
+911% +$295K ﹤0.01% 4691
2016
Q1 		$25K Buy
3,809
+500
+15% +$3.35K ﹤0.01% 5851
2015
Q4 		$28K Sell
3,309
-2,286
-41% -$17.3K ﹤0.01% 5928
2015
Q3 		$30K Buy
5,595
+1,073
+24% +$6.75K ﹤0.01% 5915
2015
Q2 		$26K Buy
4,522
+804
+22% +$5.5K ﹤0.01% 6065
2015
Q1 		$24K Sell
3,718
-4,105
-52% -$19.8K ﹤0.01% 6005
2014
Q4 		$36K Sell
7,823
-1,392
-15% -$9.15K ﹤0.01% 5900
2014
Q3 		$74K Sell
9,215
-4,158
-31% -$37K ﹤0.01% 5590
2014
Q2 		$129K Sell
13,373
-12,924
-49% -$132K ﹤0.01% 5377
2014
Q1 		$310K Buy
26,297
+14,356
+120% +$242K ﹤0.01% 4871
2013
Q4 		$184K Buy
+11,941
New +$92K ﹤0.01% 5066

Other funds holding ORMP

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
AF
Aquamarine Financial George Town $1.37B AUM
Mercer Global Advisors
Mercer Global Advisors Denver, Colorado $67.6B AUM 18.3% 1-Year Est. Return
GIA
Gem Investment Advisors Teaneck, New Jersey $102M AUM
M
Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
RG
Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Morgan Stanley's ORMP Position: Q1 2026 in Review

Morgan Stanley reduced its Oramed Pharmaceuticals (ORMP) stake by 20% in Q1 2026, selling an estimated $12.2K and leaving 14,052 shares worth $47.8K. The position accounts for ﹤0.01% of the portfolio, ranked #6440.

Morgan Stanley first reported a position in ORMP in Q4 2013 and has held it in 50 quarters since. The position peaked at $5.52M in Q4 2021. 64 funds tracked by Wall St. Rank hold ORMP as of Q1 2026.

  • Morgan Stanley held 14,052 shares of Oramed Pharmaceuticals worth $47.8K as of Q1 2026.
  • Morgan Stanley sold 3,582 Oramed Pharmaceuticals shares in Q1 2026, an estimated $12.2K.
  • Oramed Pharmaceuticals made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #6440 holding.
  • Morgan Stanley first reported a position in Oramed Pharmaceuticals in Q4 2013 and has held it in 50 quarters since.
  • Morgan Stanley's Oramed Pharmaceuticals position peaked at $5.52M in Q4 2021.
  • 64 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.